| Fund ID | 805-3924328618 |
| Fund type | Venture Capital Fund |
| 3(c)(1) exclusion | Yes |
| 3(c)(7) exclusion | No |
| Master fund | No |
| Feeder fund | No |
| Fund of funds | No |
| Relies on exemption from registration | Yes |
| Annual audit | No |
| Prepared per GAAP | No |
| Sub-advised | No |
| Sales limited to qualified investors | Yes |
| % of assets independently valued | 0% |
| Owned by the adviser or related persons | 14% |
| Owned by funds of funds | 0% |
| Owned by non-U.S. persons | 0% |
| Fund | Type | Gross assets |
|---|---|---|
| Solas Bioventures Emerging Healthcare Fund, LP | Venture Capital | $51.9M |
| Solas Bioventures Fund II, LP | Venture Capital | $34.3M |
| Solas Francis Sidecar | Venture Capital | $24.5M |
Solas MacLellan Group JV reports $7.7 million in gross assets, among the top 80% of private funds by size.
The stated minimum investment is $50,000.
Solas MacLellan Group JV is managed by Solas Bioventures Management, LLC.
No. Private funds are not required to publicly disclose performance. Form ADV reports assets, structure, and service providers.